Le Lézard
Classified in: Health
Subjects: RCL, PSF

Advisory - Bayer expands recall of RestoraLAX, sold nationwide, due to potential choking hazard


OTTAWA, July 8, 2017 /CNW/ -

Issue
Further to a recent recall of RestoraLAX 45+10, Health Canada is advising Canadians that Bayer Inc. is expanding its voluntary recall to include specific lots of RestoraLAX 30+7 Bonus Packs sold at various retailers across Canada due to a potential choking hazard.

Specific lots of RestoraLAX 30+7 Bonus Packs may contain deposits such as clumps or lumps.? The presence of these deposits may pose a choking hazard.

RestoraLAX is used to relieve occasional constipation and irregularity.

Who is affected

Affected products
The following lots of RestoraLAX 30+7 Bonus Packs (DIN 02318164):

This product is sold as a combination pack: 1 bottle of 30 doses of RestoraLAX powder, shrink wrapped together with 1 bottle of 7 doses of RestoraLAX powder.

What consumers should do

What Health Canada is doing
Health Canada is monitoring the company's recall. If new safety information is identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background
Bayer Inc. has advised that the issue is associated with a packaging process specific to the RestoraLAX® 45+10 Value Packs and the RestoraLAX 30+7 Bonus Packs, and that no other RestoraLAX packaging formats are impacted or being recalled at this time.

Related links:

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...



News published on and distributed by: